Fig. 2

Salirasib enhances Exo2-induced repression of phospho-ERK1/2 and proliferation in prostate cancer cells. a Various cancer cell lines were treated with the indicated concentrations of salirasib for 72 h, and cell proliferation was determined by MTS assays. b DU145 and PC3 cells were treated with 50 μM salirasib for the indicated times, and cell lysates were collected for Western blot with the indicated antibodies. c DU145, PC3 and LNCaP cells were treated with 50 μM Exo2 and 50 μM salirasib for 24 h, alone or in combination, and cell lysates were collected for Western blot with the indicated antibodies. d DU145 and PC3 cells were treated with 50 μM Exo2 and 50 μM salirasib for 72 h, alone or in combination, and cell proliferation was determined by MTS assays. **p < 0.01